15-SORRENTO-Therapeutics-Logo-FINAL.png
FDA Clears Sorrento Phase 2 Trial Of Non-Opioid Product Candidate Resiniferatoxin (RTX) For Treatment of the Knee Pain in Osteoarthritis (OA) Patients
July 06, 2021 14:34 ET | Sorrento Therapeutics, Inc.
Phase 2 trial of RTX for OA pain to proceed following FDA clearance.Phase 1b data demonstrated RTX safety for a single intra-articular administration without dose limiting toxicity (DLT) at any doses...
RYAH logo.jpg
RYAH Group, Inc Publishes Report on Medical Cannabis Use for Pain
June 10, 2021 08:00 ET | Potbotics, Inc. o/a RYAH
TORONTO, June 10, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- RYAH Group, Inc. (CSE:RYAH) (“RYAH” or the “Company”) is pleased to announce that its wholly owned subsidiary, RYAH Medtech Inc. ("RYAH...
TrevenaLogo.jpg
Trevena, Inc. to Participate at the Sachs Associates 4th Annual Neuroscience Innovation Forum
April 29, 2021 07:00 ET | Trevena Inc.
CHESTERBROOK, Pa., April 29, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central...
HC2 Logo.jpg
HC2 Holdings Portfolio Company R2 Technologies Receives Final Tranche of $30 Million Investment
February 03, 2021 08:45 ET | HC2 Holdings, Inc.
NEW YORK, Feb. 03, 2021 (GLOBE NEWSWIRE) -- HC2 Holdings, Inc. (“HC2” or “the Company”) (NYSE: HCHC) today announced that R2 Technologies Inc. ("R2"), founded by HC2’s portfolio company Pansend Life...
Sorrento Releases Positive Results of Phase 1B Trial of Resiniferatoxin (RTX) In Reduction of OsteoArthritis (OA) Knee Pain
September 28, 2020 09:00 ET | Sorrento Therapeutics, Inc.
Phase 1b safety data at 6 month post-administration and Day 84 efficacy data available for all patients enrolled.No dose limiting toxicities at any of the doses tested (up to 30 ug) at 6 months...
AMR Logo.png
Pain Management Devices Market to Reach $6.77 Billion by 2026 at 6.7% CAGR
August 26, 2020 10:15 ET | Allied Market Research
Portland, OR, Aug. 26, 2020 (GLOBE NEWSWIRE) -- According to the report, the global pain management devices industry accounted for $4.01 billion in 2018, and is anticipated to reach $6.77 billion by...
Berg Nutrition Brings a Unique Form of Pure Capsaicin Called aXivite to U.S. Marketplace
July 28, 2020 10:02 ET | Berg Nutrition
ANN ARBOR, Mich., July 28, 2020 (GLOBE NEWSWIRE) -- Berg Nutrition has been named the exclusive U.S. distributer of the branded ingredient, aXivite phenylcapsaicin, a synthetic, innovative form of...
Biotricity.jpg
Biotricity Launches Innovative Pain Management Product with NeuPath Health
March 10, 2020 08:00 ET | biotricity
REDWOOD CITY, Calif., March 10, 2020 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB: BTCY), a medical diagnostic and consumer healthcare technology company, today announced that it has launched its...
15-SORRENTO-Therapeutics-Logo-FINAL.png
Sorrento to Present Late Breaking Positive Clinical Trial Data for Resiniferatoxin at Two Prestigious Upcoming Pain Conferences
January 27, 2020 07:00 ET | Sorrento Therapeutics, Inc.
Phase 1b/2 OA Knee Pain study completed enrollment of 93 patients, with no dose limiting toxicities observed and significant efficacy signal confirmed in expansion cohorts. The program is expected to...
ADYNXX_CLEAR.png
Adynxx Reports Third Quarter 2019 Financial Results
November 14, 2019 06:00 ET | Adynxx, Inc.
SAN FRANCISCO, Nov. 14, 2019 (GLOBE NEWSWIRE) -- Adynxx, Inc. (OTCQB: ADYX), a clinical-stage biopharmaceutical company focused on the development of transcription factor decoy technology and...